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Objective.  Although a number of reports have documented a significantly increased 
incidence of HLA-DR15 in aplastic anemia (AA), the exact role of HLA-DR15 in the 
immune mechanisms of AA remains unclear.  We herein clarify the difference 
between DRB1*1501 and DRB1*1502, the 2 DRB1 alleles which determine the 
presentation of HLA-DR15, in the pathophysiology of AA.  Materials and Methods.  
We investigated the relationships of the patients’ HLA-DRB1 allele with both the 
presence of a small population of CD55-CD59- (PNH-type) blood cells and the 
response to antithymocyte globulin (ATG) plus cyclosporine (CsA) therapy in 140 
Japanese AA patients.   Results.  Of the 30 different DRB1 alleles, only DRB1*1501 
(33.6% vs. 12.8%, Pc<0.01) and DRB1*1502 (43.6% vs. 24.4%, Pc<0.01) displayed 
significantly higher frequencies among the AA patients than among a control.  AA 
patients possessing HLA-DR15 tended to be old, and especially, the frequency of 
DRB1*1502 in patients ≥40 years old (52.4%) was markedly higher than that in those 
<40 years old (16.2%, Pc<0.01).  Only DRB1*1501 was significantly associated with 
the presence of a small population of PNH-type cells and it also showed a good 
response to ATG plus CsA therapy in a univariate analysis.  A multivariate analysis 
showed only the presence of a small population of PNH-type cells to be a significant 
factor associated with a good response to the immunosuppressive therapy (P<0.01).   
Conclusion.  Although both DRB1*1501 and DRB1*1502 contribute to the 
development of AA, the methods of contribution differ between the two alleles. 
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INTRODUCTION 
Aplastic anemia (AA) is a syndrome characterized by pancytopenia and bone marrow 
hypoplasia.  Although the etiology remains unclear, the immune destruction of 
hematopoietic stem cells has been considered the most important mechanism of bone 
marrow failure in AA [1].  One important finding supporting the role of such 
autoimmune mechanisms in AA is the high incidence of a certain HLA allele in AA 
patients.  A number of reports have documented a significantly increased incidence of 
HLA-DR2 or the split antigen HLA-DR15 in AA [2-5].  We previously demonstrated 
a strong association between DRB1*1501 and a susceptibility to AA, in which the 
hematopoietic function improves with the administration of cyclosporin A (CsA) [6].  
Some reports have also demonstrated that HLA-DR15 or DRB1*1501 can predict the 
response to immunosuppressive therapy (IST) in patients with AA and 
myelodysplastic syndrome (MDS) [7-9], while others have failed to identify HLA-
DR15 as a predictor for the response to ATG therapy [3,10,11].   In our previous 
study, AA patients carrying DRB1*1502, another major allele corresponding to HLA-
DR15 in Japanese, did not show a better response to CsA than those without HLA-
DR15 [6].  The exact role of HLA-DR15 in the immune mechanisms of AA thus 
remains unclear, probably due to both the low number of patients that have been 
studied for DRB1 alleles and the general heterogeneity in the pathogenesis of AA. 
Another interesting aspect of HLA-DR15 is the association with the expansion of 
paroxysmal nocturnal hemoglobinuria (PNH) clones.  Several studies have revealed 
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the frequency of HLA-DR15 to be significantly higher in patients with AA and MDS 
possessing PNH-type blood cells and in florid PNH than in normal controls [10,12], 
however, the relationship between DRB1 alleles corresponding to DR15 and 
increased PNH-type cells in AA has not yet been studied in detail.  The close 
relationship between HLA-DR15 and the expansion of PNH clones suggests that the 
T-cell responses against certain antigen presented by HLA-DR15 or other HLA-class 
II alleles in linkage disequilibrium with DR15 in hematopoietic stem cells may cause 
bone marrow failure, thus allowing PNH-type stem cells to survive.  
We previous demonstrated the frequency of HLA-DR15 to markedly increase in 
patients with MDS-refractory anemia (RA) and a small population of PNH-type cells 
(more than 0.003% for granulocyte, more than 0.005% for RBCs), as demonstrated by 
sensitive flow cytometry [13].  In that study, RA patients possessing a small 
population of PNH-type cells displayed favorable responses to CsA.  An investigation 
of a large number of AA patients treated with IST using the same methods to detect 
small populations of PNH-type cells would thus clarify the role of DRB1 alleles 
corresponding to HLA-DR15 and PNH-type cells in the immune mechanisms of AA 
and their mutual relationships.  To test this hypothesis, we investigated the 
relationship between the DRB1 allele in such patients and both the presence of a small 
population of PNH-type cells and the response to ATG plus CsA therapy in 140 
Japanese AA patients.   
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MATERIALS AND METHODS 
Patients 
Table 1 summarizes the patient characteristics.  The 140 Japanese AA patients were 
diagnosed at Kanazawa University Hospital, hospitals which participate in a 
cooperative study led by the Intractable Disease Study Group of Japan and other 
referring institutions from April 1999 through November 2005.  The study subject 
included 77 patients who were tested for any correlation between the presence of a 
minor population in PNH-type cells and the response to IST in our previous study 
[14].  The severity of AA was classified according to the criteria proposed by Camitta 
et al [15,16].  All participants provided written, informed consent to all procedures 
associated with the study, which was approved by the Ethical Committee at our 
institution (study number 46).  This study also conforms to the recently revised tenets 
of the Helsinki protocol. 
 
Detection of PNH-type cells 
We performed two-color flowcytometry of the granulocytes and RBCs according to 
our previously described method  [14,17,18].  First, 3-5 mL of heparinized blood was 
drawn from each patient.  To detect the PNH-type granulocytes, phycoerythrin (PE)-
labeled anti-CD11b monoclonal antibodies (MoAbs; Becton Dickinson, Mountain 
View, CA), fluorescein-isothiocyanate (FITC)-labeled anti-CD55 MoAbs (clone IA10, 
mouse IgG2a; Pharmingen, San Diego, CA), and FITC-labeled anti-CD59 MoAbs 
 6
(clone p282, mouse IgG2a; Pharmingen) were used in combination with isotype-
matched control MoAbs, as previously described.  To detect the PNH-type RBCs, PE-
labeled anti-glycophorin A MoAbs (clone JC159, DAKO, Glostrup, Denmark) were 
used instead of anti-CD11b MoAbs.  Fresh blood was diluted to 3% using phosphate-
buffered saline (PBS), and 50 mL of diluted blood was incubated with 4 mL of PE-
labeled anti-glycophorin A MoAbs, FITC-labeled anti-CD55 and anti-CD59 MoAbs 
on ice for 25 minutes.  A total of at least 1 ×105 CD11b+ granulocytes and 
glycophorin A+ RBCs within each corresponding gate were analyzed using FACScan 
flow cytometry (Becton Dickinson).  In order to avoid any false positive results, we 
excluded CD11bdim and glycophorin Adim cells from the analyses using careful gating 
because these cells include damaged cells those are often mistakenly judged to be 
PNH-type cells due to their poor binding to anti-CD55 and anti-CD59 MoAbs.  This 
flow cytometry method failed to detect 0.003% or more CD55-CD59-CD11b+ 
granulocytes or 0.005% or more CD55-CD59-glycophorin-A+ RBCs in any of 183 
healthy individuals.  We therefore defined the presence of more than 0.003% CD55-
CD59-CD11b+ granulocytes CD55-CD59-glycophorin-A+ RBCs to be abnormal 
[14,18]. 
 
Determination of DRB1 alleles 
DRB1 alleles of 140 AA patients and 491 healthy Japanese randomly selected from 
general population [19] were determined using polymerase chain reactions with 
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sequence-specific primers (PCR-SSP) (Micro SSP HLA DNA typing trays; One 
Lambda, Canoga Park, CA).  Genomic DNA was prepared from blood samples using 
a DNA extraction kit (Generation capture column kit; Gentra, Minneapolis, MN). 
  
ATG plus CsA therapy and response criteria 
Seventy-seven of 140 patients (55.0%) were treated with antithymocyte globulin 
(ATG, Lymphoglobuline, Aventis Behring, King of Prussia, PA, 15 mg/kg/day, 5 
days) and cyclosporin (CsA, Novartis, Basel, Switzerland, 6 mg/kg/day) within 1 year 
of diagnosis.  The dose of CsA was adjusted to maintain trough levels at between 150 
and 250 ng/mL and the appropriate dose was administered for at least 6 months.  
Granulocyte colony-stimulating factor (G-CSF, filgrastim, 300 μg/m2 or lenograstim, 
5 μg/kg) was administered to some patients.  The response to ATG plus CsA therapy 
was evaluated according to the response criteria described by Camitta [20].  A 
complete response (CR) was defined as hemoglobin normal for age, neutrophil count 
more than 1.5 x 109/L, and platelet count more than 150 x 109/L.  A partial response 
(PR) was defined as transfusion independent and no longer meeting the criteria for 
severe disease in patients with severe AA, and it was defined as transfusion 
independence (if previously dependent) or doubling or the normalization of at least 
one cell line or an increase in the baseline hemoglobin of more than 30 g/L (if initially 
less than 60 g/L), a neutrophil count of more than 0.5 x 109/L (if initially less than 0.5 
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x 109/L), and a platelet count of more than 10 x 109/L (if initially <20 x 109/L) in 
patients with moderate AA. 
 
Statistical analysis 
The allele frequency defined as the proportion of patients with at least one copy of a 
specific gene was determined by direct counting.  The χ2 test compared the allele 
frequencies of HLA-DRB1 between the patient groups and a Japanese control 
population, composed of 491 healthy unrelated individuals selected at random from 
the general population [19].   The corrected value of P (Pc) was calculated by 
multiplying P with the number of alleles tested (n=30).  The χ2 test, Fisher exact test 
and logistic procedures [21] analyzed associations between the prevalence of 
increased PNH-type cells and genetic factors, and between individual pretreatment 
variables and the response to ATG plus CsA therapy.  The Kaplan-Meier methods 
graphically compared the cumulative incidence of the response to ATG and CsA 
therapy and the time to event, while the log-rank test analyzed differences between 
the patients who possess HLA-DRB1*1501, DRB1*1502 and DRB1 alleles other 
than these two alleles.  All statistical analyses were performed using the JMP version 




Frequencies of DRB1 alleles in AA patients 
Table 2 summarizes the frequencies for the 30 different DRB1 alleles identified in the 
140 AA patients and 491 controls.  Only the frequencies of DRB1*1501 (33.6% vs. 
12.8%, Pc<0.01, Odds ratio=3.43) and DRB1*1502 (43.6% vs. 24.4%, Pc<0.01, Odds 
ratio =2.39) were significantly higher among the AA patients than among controls.  
Figure 1 illustrates the numbers of patients with DRB1*1501 and/or DRB1*1502 and 
the patients without either of the two alleles in the different age groups.  Two peaks in 
the age distribution of the patients were noted, namely, at 20 to 29-years-old and at 60 
to 79-years-old.  After dividing the patients into young (<40-years-old, n=37) and old 
(≥40-years-old, n=103) groups, 82.5% of patients in the older group carried at least 
one of DRB1*1501 or DRB1*1502.  The frequency of DRB1*1502 in the older group 
(54 of 103 patients, 52.4%) was significantly higher (Pc=0.03) than that in the 
younger group (6 of 37 patients, 16.2%).  No significant difference in the frequency 
of DRB1*1501 was identified between the two groups (36 of 103 patients, 35.0% vs. 
11 of 37 patients, 29.7%, P=0.56).   
 
Prevalence of patients possessing PNH-type cells 
A wide range of PNH-type granulocytes (0.005% to 23.0%; median, 0.153%) and 
PNH-type RBCs (0.007% to 6.57%; median, 0.094%) were detected in 92 of 140 
(65.7%) AA  patients.  When the patients were divided into four groups according to 
the presence of DRB1*1501 and DRB1*1502, the proportions of PNH+ patients were 
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66.7% (4 of 6 patients) in the DRB1*1501+1502+ patients, 85.3% (35 of 41 patients) 
in DRB1*1501+1502-, 59.3% (32 of 54 patients) in DRB1*1501-1502+ and 53.8% (21 
of 39 patients) in DRB1*1501-1502-. 
 
Allele frequencies in the PNH+ and PNH- AA patients 
We next divided the 140 AA patients for whom both DRB1 alleles were determined 
into PNH+ patients (n=92) and patients without a small population of PNH-type cells 
(PNH- patients, n=48), and then compared the frequency of each DRB1 allele among 
the three different groups including the PNH+ patients, PNH- patients and controls 
(Fig. 2).  The frequency of DRB1*1501 compared to the controls was significantly 
higher in only the PNH+ patients (39 of 92 patients, 42.4%, Pc<0.01), not in PNH- 
patients (8 of 48 patients, 16.7%).  On the other hand, the frequency of DRB1*1502 
in comparison to the controls was higher in both the PNH+ patients (37 of 92 patients, 
40.2%, Pc =0.05) and PNH- patients (24 of 48 patients, 50.0%).  The frequencies of 
other DRB1 alleles, including DRB1*0405, were similar among PNH+ patients, PNH- 
patients, and controls. 
 
Correlation of HLA-DR15 alleles with the prevalence of increased PNH-type 
cells in AA patients 
We analyzed the associations between the prevalence of PNH-type cells and genetic 
factors, such as age, sex, severity, chromosomal abnormality and HLA-DRB1 allele 
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to determine which factors might contribute to a slight increase in PNH-type cells in 
our AA patients.   The presence of DRB1*1501 (P<0.01, Odds ratio=3.68) was the 
only significant factor associated with an increase in the proportion of PNH-type cells 
based on a univariate analysis, and a multivariate analysis confirmed this result 
(P<0.01).  The presence of DRB1*1502 was not considered to be a contributing factor.   
 
Favorable factors affecting response to ATG plus CsA therapy 
Fifty-five of 77 patients (71.4%) improved with ATG plus CsA therapy.  The factors 
favorably affecting the response to IST in the AA patients were examined under a 
univariate and multivariate analysis (Table 3).  Only the presence of PNH-type cells 
was significantly associated with the response to IST based on a multivariate analysis.  
After taking into account the kinetics of the response to treatment, we made Kaplan-
Meier curves to determine the probability of response to IST in 3 different groups of 
patients as defined by DRB1 alleles (Fig. 3).  There were significant differences in the 
probability of the response to IST between the DRB1*1501+1502- patients and either 
the DRB1*1501-1502+ patients (P<0.01) or the DR15- patients (P=0.01) (Fig. 3A).  
However, these differences in the probability of response IST were no longer 
observed when the probability of response was compared in either the PNH+ patients 




This study demonstrated for the first time that, in addition to DRB1*1501, which is a 
major DRB1 allele determining the presentation of HLA-DR15 in Caucasian [2,3] and 
Chinese populations [4], DRB1*1502 is frequently present in Japanese AA patients.  
This finding, based on a large number of patients, suggests that the DR15 molecule 
plays a definite role in the development of a subset of AA.  Another novel finding in 
the present study was that the significantly increased frequency of HLA-DR15 was 
only observed in old AA patients. The frequency of HLA-DR15 reached up to 80% in 
AA patients ≥40-years old.  The apparent age-dependent differences in HLA-DR15 
frequency suggest that the pathophysiology of AA in older patients may therefore 
differ from that in younger patients.  Several studies of Japanese pediatric patients 
have revealed a relatively high incidence of MDS secondary to AA compared to adult 
patients [22-24].   Given the lower frequency of HLA-DR15, pediatric AA may thus 
display a higher proportion of bone marrow failure caused by non-immune 
mechanisms than adult AA. 
In contrast to the findings of previous reports, DRB1*1501 appeared to confer a 
better chance of response to regimens including ATG than other DRB1 alleles, 
including DRB1*1502.  We previously demonstrated that DRB1*1501 predicts the 
response to CsA, but not to ATG [11].  In the previous study, only 6 of 59 ATG-
treated patients received CsA.  The combined use of CsA and the larger number of 
ATG-treated patients in the present study probably accounts for the different findings 
 13
regarding the role of DRB1*1501 in predicting the response to ATG therapy.  
DRB1*1501 may affect the response of AA to ATG therapy only when CsA is 
administered in combination with ATG. 
Several previous studies failed to confirm the role of HLA-DR15 in predicting 
the response to ATG [3,10].  Most previous studies analyzed DRB1 alleles using low-
resolution methods that are unable to sufficiently distinguish DRB1*1502 from 
DRB1*1501.  DRB1*1502 accounts for 3-7% of the DRB1 alleles corresponding to 
DR15 even in Caucasians [25], and this frequency may even be higher in AA patients, 
particularly among AA patients ≥40-years-old.  As a result, some patients with DR15 
who did not respond to ATG in previous studies may have been DRB1*1502+, rather 
than DRB1*1501+.  The results of this study indicate the importance of accurately 
determining the DRB1 alleles using high-resolution methods to clarify the role of 
HLA-DR15 in predicting a response to IST. 
A higher frequency of HLA-DR15 among PNH+ patients in comparison to PNH- 
patients has been reported by Maciejewsky et al. in 2001 [26].  The present study 
confirmed this finding using a different flow cytometry assay that distinguished PNH+ 
patients from PNH- patients using lower levels of glycosylphosphatidyl inositol-
anchored protein-deficient cells than the assay used in the previous study.  Our 
methods also identified a significant difference between DRB1*1501 and 
DRB1*1502 in the minimal expansion of PNH clones.  The frequencies of both 
alleles increased in the PNH+ patients in comparison to the normal controls, thus 
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supporting the preliminary results of our study of 23 patients with refractory anemia 
[13].  However, only DRB1*1501 represented a genetic factor significantly associated 
with an increase in the proportion of PNH-type cells in AA patients in the present 
study because the frequency of DRB1*1502 was high in both PNH+ and PNH- AA 
patients, thus indicating that the minimal expansion of PNH clones is not affected by 
DRB1*1502.  Together with the difference in the response rate to IST between 
DRB1*1501+ and DRB1*1502+ AA patients, all these findings suggest that 
DRB1*1501 and DRB1*1502 therefore play a different role in the pathogenesis of 
AA.   
In AA patients carrying DRB1*1501, the presentation of autoantigen by this 
molecule may readily induce a cell-mediated attack against hematopoietic stem cells 
that may be associated with the minimal expansion of a PNH clones.  Previous studies 
have demonstrated that the presence of a CD4+ T-cell attack against hematopoietic 
stem cells allows the survival of PNH-type stem cells [27,28].  On the other hand, 
polymorphic gene alleles of myelosuppressive cytokines, in linkage disequilibrium 
with DRB1*1502 may predispose individuals with HLA-DRB1*1502 towards the 
development of AA.  In keeping with this hypothesis, a recent study on diabetes 
mellitus patients revealed that a haplotype of TNFa12-DRB1*1502 was therefore 
more frequent in patients likely to develop insulin-dependency than in those who do 
not develop insulin-dependency [29].  Several reports have demonstrated TNFa12 to 
be associated with a higher secretion of TNF-alpha [30].   
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HLA-DR15 molecules derived from DRB1*1502 differ from those derived from 
DRB1*1501 in only one amino acid at position 86 (valine for DRB1*1502 and 
glycine for DRB1*1501) of the beta-chain [31].  This structural similarity indicates 
that antigenic epitopes presented by these molecules are common [32,33].  For most 
autoimmune diseases where DRB1*1501 is associated with susceptibility in patients 
from Western countries, DRB1*1502 is expected to play the same role as 
DRB1*1501 in Japanese patients.  However, in Japanese patients with multiple 
sclerosis, the frequency of DRB1*1502 is not increased in comparison to that in the 
controls [34,35].  As a result, DRB1*1502 appears to contribute to the development of 
some autoimmune diseases via different mechanisms to DRB1*1501.  In AA patients 
carrying DRB1*1501, certain antigens of which presentation requires position 86 of 
the beta-chain to be glycine may likely induce an immune system attack to 
hematopoietic progenitor cells.  It is also possible that DRB5*0101 and DRB5*0102, 
which are in complete linkage disequilibrium with DRB1*1501 and DRB1*1502, 
respectively, in the Japanese population [19] may be responsible for the difference 
because DRB5*0101 differs from DRB5*0102 by 3 amino acids in the antigen-
peptide binding domain.   
Our data may be relevant to the management of AA.  Although the incidence of 
HLA-DR15 is significantly higher in AA patients than in the normal controls, only 
DRB1*1501 was found to be a predictive marker for a good response to ATG plus 
CsA therapy.  AA patients with DRB1*1502 who do not show an increased 
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proportion of PNH-type cells may not benefit from IST.  HLA-DR typing has been 
considered to be useful for predicting a good response to IST in AA patients[7,8], but 
this costly test may not be necessary in the circumstance where the highly sensitive 
flow cytometry is available because the presence of a small population of PNH-type 
cells is the only significant factor that affects the response to ATG plus CsA therapy 
based on the findings of our multivariate analysis.  Prospective studies are called for 
to confirm these findings. 
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FIGURE LEGENDS  
 
Figure 1: Age distribution of AA patients with or without HLA-DR15 
 The number of AA patients with or without HLA-DR15 in different age 
groups is shown.  DRB1*1501+1502+, patients with both DRB1*1501 and 
DRB1*1502; DRB1*1501+1502-, patients with DRB1*1501 but not DRB1*1502; 
DRB1*1501-1502+, patients with DRB1*1502 but not DRB1*1501; DRB1*1501-
1502-, patients with neither DRB1*1501 nor DRB1*1502.   
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 Figure 2.  HLA-DRB1 allele frequencies in PNH+ and PNH- AA patients 
 Frequencies of the three alleles, DRB1*1501, DRB1*1502, and DRB1*0405 
are compared in the PNH+ AA patients, PNH- AA patients, and controls. 
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 Figure 3.  Kinetics of response to ATG plus CsA therapy. 
 Kaplan-Meier curves for the response in the different groups of patients based 
on the DRB1 alleles are shown.  DRB1*1501+1502+ patients were not showed in this 
figure because only one patient (he was PNH+) was available for the analysis.  A, All 





Table 1. Patient characteristics  
Characteristics Number Range 
Total (n) 140 NA 
Age at diagnosis (y) 60 12-92 
Gender: Male/female  65/75 NA 
Severity: Severe/moderate 65/75 NA 
Neutrophil count (x 109/L) 720 0-2226 
Platelet count (x 109/L) 20 2-118 
Reticulocyte count (x 109/L) 28 2-106 
No. of patients with clonal abnormality (n) 11 NA 











Table 2. Frequencies of HLA-DRB1 alleles in Japanese AA patients and 
controls 
 AA patients         (n = 140)  
Controls            
(n = 491) HLA-DRB1 
allele 




0101  10 7.1  64 13.0 NS 
0301  0 0.0  4 0.8 NS 
0401  2 1.4  17 3.5 NS 
0403  4 2.9  18 3.7 NS 
0404  0 0.0  2 0.4 NS 
0405  35 25.0  129 26.3 NS 
0406  5 3.6  32 6.5 NS 
0407  2 1.4  2 0.4 NS 
0409  0 0.0  1 0.2 NS 
0410  1 0.7  17 3.5 NS 
0701  0 0.0  2 0.4 NS 
0801  0 0.0  0 0.0 NS 
0802  6 4.3  36 7.3 NS 
0803  8 5.7  84 17.1 NS 
0901  36 25.7  148 30.1 NS 
1001  2 1.4  2 0.4 NS 
1101  7 5.0  22 4.5 NS 
1201  7 5.0  34 6.9 NS 
1202  2 1.4  12 2.4 NS 
1301  0 0.0  4 0.8 NS 
1302  11 7.9  61 12.4 NS 
1401  2 1.4  21 4.3 NS 
1402  0 0.0  2 0.4 NS 
1403  4 2.9  13 2.6 NS 
1405  4 2.9  18 3.7 NS 
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1406  2 1.4  10 2.0 NS 
1407  0 0.0  1 0.2 NS 
1501  47 33.6  63 12.8 <0.01 
1502  61 43.6  120 24.4 <0.01 
1602  2 1.4  4 0.8 NS 
*Allele frequencies were determined by dividing the number of patients carrying 
one or two specific alleles by the total number of individuals. 
**Corrected P value (Pc) was calculated by multiplying the P value with the 






















Gender (male vs. female) 0.32 0.47 
Age (at least 40 y vs. younger) 0.79 0.37 
Severity (severe vs. moderate) 0.61 0.86 
HLA-DRB1*1501 (positive vs. negative) 0.03 0.19 
HLA-DRB1*1502 (positive vs. negative) 0.61 0.46 
PNH-type cells  (positive vs. negative) <0.01 <0.01 
*P value derived from Fisher's exact probability test. 
**P value derived from the Wald c2 test for a logistic regression model. 
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